Walleye Capital LLC Uni Qure N.V. Call Options Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $27,024 - $39,696	-4,800 Reduced 96.0%	200 $1,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $33,550 - $59,150	5,000 New	5,000 $33,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $56,100 - $69,210	3,000 New	3,000 $60,000
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $112,650 - $169,350	-2,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $59,408 - $119,392	1,600 Added 177.78%	2,500 $179,000
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $7,872 - $15,360	200 Added 28.57%	900 $35,000
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $84,416 - $131,504	-1,600 Reduced 69.57%	700 $55,000
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $62,997 - $157,343	2,300 New	2,300 $137,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.